Growth Hormone May Protect Bones
Women who want to give their bones a break may now have another tool in the toolbox.
Breast Cancer Rx Might Prevent Early Menopause
It’s good news for young women who have had breast cancer treatment and still want a baby. A medication called goserelin may help prevent the ovarian failure often caused by chemotherapy.
Hot Flashes May Signal Fracture Risk
Hot flashes and night sweats could be more than just unpleasant symptoms of menopause — they could be tied to bone health.
Fracture Was Hard to Predict in Some Postmenopausal Women
Screening tools can help doctors predict which postmenopausal women may have a broken bone due to osteoporosis in the next few years. But those tools may not accurately predict fracture risk in younger postmenopausal women.
Rx Tag-Team Works Better for Weak Bones
When one medicine doesn't help postmenopausal women with osteoporosis, doctors might recommend another. But if the second doesn't strengthen bones, what happens then? Taking them together might do the trick.
Extra Vitamins Don't Always Fill the Void
Weaker bones that come with menopause might spur some women to load up on calcium and vitamin D. But supplements might not be enough to protect bones and prevent fractures.
More Than Hot Flashes
Hot flashes are a biggie among middle-aged women. But common effects of menopause can differ around the world. New research has identified a number of different symptoms among menopausal women with osteoporosis and cardiovascular disease.
Move Aside Milk, Alcohol May Help Bone Loss
While the apple can keep the doctor away, alcohol may help keep bones from going away. Researchers say if middle-aged women drink a glass or two of alcohol each day, their bones may be stronger.
Subtle Long-Term Impacts of Child Abuse
Experiencing abuse as a child means more than a higher risk of mental illness. Researchers are learning that abused children are at risk for various long-term physical issues as well.
European Drug for Menopause and Osteoporosis
Pfizer Inc. announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for postmenopausal women with a uterus for the treatment of estrogen deficiency symptoms and treatment of osteoporosis in women at risk of fracture.